Your patients with symptomatic severe aortic stenosis (sSAS) have a chance for optimal outcomes with TAVR—including low-risk patients.2 Explore the broadened eligibility of TAVR.
SUSAN, age 73
Low surgical risk
TAVR Patient
AS disease progression: Severe AS, symptoms include decreased exercise tolerance
AS disease progression: Severe AS, symptoms include decreased exercise tolerance
NYHA class: II
Frailty indicators: 0
Surgical risk score: 2%
Comorbidities: None
QoL expectations: Retired nurse who enjoys frequent travel, working out, and bike rides. She looks forward to an extended life expectancy due to her age and active lifestyle.
DAVID, age 81
Intermediate surgical risk
TAVR Patient
AS disease progression: Severe AS, symptoms include fatigue and dyspnea upon exertion
Help your patients understand the differences between TAVR and SAVR
Using visual aids such as this side-by-side chart gives your patients with SAS a clearer understanding of their treatment options, while reinforcing their role in shared decision-making.
SAVR
TAVR
Available for all surgical risk patients (except prohibitive risk)3
OR
Available for severe, symptomatic calcific aortic stenosis patients, independent of surgical risk
More invasive procedure
OR
Less invasive procedure4
Requires sternotomy
OR
The most common approach is the transfemoral approach
Requires stopping the heart and connecting the patient to a blood-pumping machine
OR
Does not require stopping the heart
Requires general anesthesia
OR
May be performed using conscious sedation
On average, may take ~4 hours*
OR
On average, may take ~1 hour*4
With TAVR, most patients have a short recovery time and go home the next day
*The PARTNER 3 Trial, transcatheter or surgical aortic valve replacement in low-risk patients with aortic stenosis.
Peer Perspectives:
Treating aortic stenosis at the right time
“It really does negatively impact the patient when we wait to treat them.”
-
Antonio H. Frangieh, MD Interventional Cardiologist
COMORBIDITIES... OR SYMPTOMS OF SAS?
Or is it their age and/or preexisting health conditions? Find out why comorbidities should not delay referrals.5
References:1.Nkomo VT, Gardin JM, Skelton TN, et al. Burden of valvular heart diseases: a population-based study. Lancet. 2006;368(9540):1005-1011.2.Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med. 2019;380(18):1695-1705.3.Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: Executive summary: A report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. Circulation. 2021;143(5):e72-e227.4.Cleveland Clinic. Transcatheter aortic valve replacement. Updated August 31, 2023. Accessed February 29, 2024. https://my.clevelandclinic.org/health/treatments/17570-transcatheter-aortic-valve-replacement-tavr5.Feldman DR, Romashko MD, Koethe B, et al. Comorbidity burden and adverse outcomes after transcatheter aortic valve replacement. J Am Heart Assoc. 2021;10(10):e018978.
Patients and/or clinicians quoted on this website have received compensation from Edwards Lifesciences.
You are about to leave TreatHeartValveFailure.com
By clicking this link, you understand that the website that you will be taken to is not controlled or endorsed by Edwards Lifesciences (“Edwards”), and Edwards does not own, control or influence the content found on the third-party website. You also understand that Edwards does not own or control any first- or third-party advertising, marketing or analytics technologies that may be on the third-party website.